Outpatient metformin use is associated with reduced severity of COVID-19 disease in adults with overweight or obesity Open Access (recommended)
Bramante CT, Buse J, Tamaritz L, Palacio A, Cohen K, Vojta D, Liebovitz D, Mitchell N, Nicklas J, Lingvay I, Clark JM, Aronne LJ, Anderson E, Usher M, Demmer R, Melton GB, Ingraham N, Tignanelli CJ. Outpatient metformin use is associated with reduced severity of COVID-19 disease in adults with overweight or obesity. Journal of Medical Virology. 2021;93(7):4273-4279.
Descriptions
- Resource type(s)
- Article
- Keyword
- COVID-19
- Rights
- Attribution-NonCommercial-NoDerivs 3.0 United States
- Creator
-
Bramante, Carolyn T.
Buse, John
Tamaritz, Leonardo
Palacio, Ana
Cohen, Ken
Vojta, Deneen
Liebovitz, David M
Mitchell, Nia
Nicklas, Jacinda
Lingvay, Ildiko
Clark, Jeanne M.
Aronne, Louis J.
Usher, Michael
Demmer, Ryan
Melton, Genevieve B.
Ingraham, Nicholas
Tignanelli, Christopher J.
Anderson, Erik William
- Abstract
-
Observational studies suggest outpatient metformin use is associated with reduced mortality from coronavirus disease-2019 (COVID-19). Metformin is known to decrease interleukin-6 and tumor-necrosis factor-alpha, which appear to contribute to morbidity in COVID-19. We sought to understand whether outpatient metformin use was associated with reduced odds of severe COVID-19 disease in a large US healthcare data set. Retrospective cohort analysis of electronic health record (EHR) data that was pooled across multiple EHR systems from 12 hospitals and 60 primary care clinics in the Midwest between March 4, 2020 and December 4, 2020. Inclusion criteria: data for body mass index (BMI) > 25 kg/m(2) and a positive SARS-CoV-2 polymerase chain reaction test; age >= 30 and <= 85 years. Exclusion criteria: patient opt-out of research. Metformin is the exposure of interest, and death, admission, and intensive care unit admission are the outcomes of interest. Metformin was associated with a decrease in mortality from COVID-19, OR 0.32 (0.15, 0.66; p = .002), and in the propensity-matched cohorts, OR 0.38 (0.16, 0.91; p = .030). Metformin was associated with a nonsignificant decrease in hospital admission for COVID-19 in the overall cohort, OR 0.78 (0.58-1.04, p = .087). Among the subgroup with a hemoglobin HbA1c available (n = 1193), the adjusted odds of hospitalization (including adjustment for HbA1c) for metformin users was OR 0.75 (0.53-1.06, p = .105). Outpatient metformin use was associated with lower mortality and a trend towards decreased admission for COVID-19. Given metformin's low cost, established safety, and the mounting evidence of reduced severity of COVID-19 disease, metformin should be prospectively assessed for outpatient treatment of COVID-19.
- Related URL
- Publisher
-
WILEY
- Date Created
-
2021-07
- Original Identifier
- (PMID) 33580540
- Grants and funding
-
Agency for Healthcare Research and Quality (AHRQ)United States Department of Health & Human ServicesAgency for Healthcare Research & Quality; Patient-Centered Outcomes Research Institute (PCORI)Patient-Centered Outcomes Research Institute - PCORI [K12HS026379]; National Center for Advancing Translational SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2TR002492, UL1TR002494, UL1TR002489]; National Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [NIH NHLBI T32HL07741, 1K23HL133604]; COVID-19 Rapid response grant [UM 2020-2231]; Minnesota Learning Health System Mentored Training Program (MH-LHS), M Health Fairview Institutional Funds
- DOI
-
10.1002/jmv.26873
File Details
- File Properties
-
Mime type: application/pdf
File size: 1316.9 kB